Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

Sales growth at CER, which is a Non GAAP measure, is computed by restating 2011 results using average 2010 foreign exchange rates for the relevant period.

Average exchange rates for the nine months to September 30, 2011 were $1.61:£1.00 and $1.41:€1.00 (2010: $1.54:£1.00 and $1.32:€1.00). Average exchange rates for Q3 2011 were $1.61:£1.00 and $1.41:€1.00 (2010: $1.55:£1.00 and $1.29:€1.00).

TRADEMARKS

All trademarks designated ® and ™ used in this press release are trademarks of Shire plc or companies within the Shire group except for 3TC® and ZEFFIX® which are trademarks of GSK, PENTASA® which is a registered trademark of FERRING B.V., CONCERTA® which is a trademark of ALZA Corporation, FABRAZYME® and CEREZYME® which are trademarks of GENZYME Therapeutic Products Limited Partnership and DAYTRANA® which is a trade mark of Noven Pharmaceuticals Inc. Certain trademarks of Shire plc or companies within the Shire group are set out in Shire's Annual Report on Form 10-K for the year ended December 31, 2010 and the Quarterly Report on Form 10-Q for the three months ended June 30, 2011.

For further information please contact:

Investor Relations
Eric Rojas, erojas@shire.com, +1-781-482-0999
Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894-157
Media

Jessica Mann (Corporate), jmann@shire.com, +44-1256-894-280
Matthew Cabrey (Specialty Pharma), mcabrey@shire.com, +1-484-595-8248
Jessica Cotrone (Human Genetic Therapies), jcotrone@shire.com, +1-781-482-9538
Lindsey Hart (Regenerative Medicine),

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... , ... August 26, 2015 , ... PRC Clinical, ... develop new business relationships with local sponsors in southern California. The Clinical Trial Management ... drug development processes and regulatory pathways., , Stem Cell ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Multiple Ultrasound Solution Provider Doubles Sales Over Same Period Last ... ... WAUKESHA, Wis., Aug. 27 MedPro Imaging, a premier,provider of ... representing a doubling of sales,over the same period last year. Recent ...
... Following the successful acquisition of,Drug Development Solutions (,DDS,) ... today that it has fully,integrated its two early ... Early Phase., Chiltern Early Phase is providing ... via its two well established units in Slough,(just ...
... Inc. (Nasdaq: AMLN ) and Eli Lilly and ... provided context and additional information,regarding the August 18, 2008 ... alert for BYETTA(R) (exenatide) injection referencing,pancreatitis. The companies were ... well as others, and previously reported these cases to ...
Cached Biology Technology:MedPro Installs 1000th Ultrasound System Worldwide 2Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... cancer as a major cause of death among children ... adequately addressed by national or international health organizations and ... Hospital. This growing rate of pediatric cancer is occurring ... is being reduced through the efforts of the World ...
... prices at the gas pump could come in the ... biomass, according to a joint feasibility study for the ... Oak Ridge National Laboratory report outlines a national strategy ... organic matter that is available on a renewable or ...
... everything was big has helped Queensland researchers to unearth ... responsible for wiping out Australian giant marsupials or megafauna ... specimens' such as giant kangaroos and wombats, the researchers ... performed the first systematic analysis of a site in ...
Cached Biology News:Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3Human Cells Filmed Instantly Messaging for First Time 2Small species back-up giant marsupial climate change extinction claim 2Small species back-up giant marsupial climate change extinction claim 3
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: